Top

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based therapies are effective for many men, there remain an estimated 20% of patients who will not benefit and have significantly worse outcomes.

These patients have a subtype of prostate cancer known as aggressive variant prostate cancer (AVPC), which does not respond to therapies that block...

Ana Aparicio, M.D.

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...

BY MD Anderson staff

This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology.

Sharma, along with Patrick Hwu, M.D., head of Cancer Medicine, and Jim Allison, Ph.D., chair of Immunology, leads the immunotherapy platform of MD Anderson’s Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical...

T cell image

BY MD Anderson staff

In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...

BY Clayton R. Boldt, Ph.D.

Excluding skin cancers, prostate cancer is the most commonly diagnosed cancer among men in the United States. According to the American Cancer...

BY Ron Gilmore

Reported online in the July 28 issue of Molecular Cell, a study conducted at MD Anderson has shown that a protein called ZMYND8 blocks expression...

BY Ron Gilmore

New findings about where and how aggressive forms of prostate cancer potentially begin may lead to new therapies for hard-to-treat and lethal...

BY Ron Gilmore

Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer...

BY Laura Sussman

Results of an MD Anderson clinical trial may change the perspective on a role for combination chemotherapy in advanced prostate cancer.